224 related articles for article (PubMed ID: 23186136)
1. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.
Siggelkow W; Boehm D; Gebhard S; Battista M; Sicking I; Lebrecht A; Solbach C; Hellwig B; Rahnenführer J; Koelbl H; Gehrmann M; Marchan R; Cadenas C; Hengstler JG; Schmidt M
BMC Cancer; 2012 Nov; 12():562. PubMed ID: 23186136
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
3. A three-gene model to robustly identify breast cancer molecular subtypes.
Haibe-Kains B; Desmedt C; Loi S; Culhane AC; Bontempi G; Quackenbush J; Sotiriou C
J Natl Cancer Inst; 2012 Feb; 104(4):311-25. PubMed ID: 22262870
[TBL] [Abstract][Full Text] [Related]
4. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
[TBL] [Abstract][Full Text] [Related]
5. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
6. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.
Schmidt M; Petry IB; Böhm D; Lebrecht A; von Törne C; Gebhard S; Gerhold-Ay A; Cotarelo C; Battista M; Schormann W; Freis E; Selinski S; Ickstadt K; Rahnenführer J; Sebastian M; Schuler M; Koelbl H; Gehrmann M; Hengstler JG
Breast Cancer Res Treat; 2011 Feb; 125(3):637-46. PubMed ID: 20352488
[TBL] [Abstract][Full Text] [Related]
7. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
[TBL] [Abstract][Full Text] [Related]
8. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells.
Jiang S; Katayama H; Wang J; Li SA; Hong Y; Radvanyi L; Li JJ; Sen S
Horm Cancer; 2010 Feb; 1(1):11-20. PubMed ID: 21761347
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
12. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
[TBL] [Abstract][Full Text] [Related]
13. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer.
Bozhanov SS; Angelova SG; Krasteva ME; Markov TL; Christova SL; Gavrilov IG; Georgieva EI
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1657-69. PubMed ID: 20177704
[TBL] [Abstract][Full Text] [Related]
14. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
15. Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2 - negative subtype.
Tanaka Y; Ohno T; Kadonaga T; Kidokoro Y; Wakahara M; Nosaka K; Sakabe T; Suzuki Y; Nakamura H; Umekita Y
Breast Cancer; 2021 Jul; 28(4):822-828. PubMed ID: 33481184
[TBL] [Abstract][Full Text] [Related]
16. Loss of circadian clock gene expression is associated with tumor progression in breast cancer.
Cadenas C; van de Sandt L; Edlund K; Lohr M; Hellwig B; Marchan R; Schmidt M; Rahnenführer J; Oster H; Hengstler JG
Cell Cycle; 2014; 13(20):3282-91. PubMed ID: 25485508
[TBL] [Abstract][Full Text] [Related]
17. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.
Yang F; Guo X; Yang G; Rosen DG; Liu J
Mod Pathol; 2011 Jun; 24(6):836-45. PubMed ID: 21441901
[TBL] [Abstract][Full Text] [Related]
18. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
19. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
